OMEROS CORPORATION

NASDAQ: OMER (Omeros Corporation)

Last update: 20 minutes ago

13.96

-0.59 (-4.05%)

Previous Close 14.55
Volume 566,426
Price / Earnings (Forward) 58.00
Price / Sales 15.79
52 Weeks Range
6.70 (-52%) — 21.24 (52%)
Diluted EPS (TTM) -3.04
Current Ratio (MRQ) 1.16
Operating Cash Flow (TTM) -142.86 M
Levered Free Cash Flow (TTM) -102.50 M
Return on Assets (TTM) -30.70%

AIStockmoo Score

-1.3
Neutral for 1 day
Earns below its cost of capital. Returns on capital falling. info
Weak profitability. Thin short-term liquidity. Negative cash flow. info
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Holdings' Value info NA
Risk Premium info NA
Market Valuation info NA
Uptrend over the past year. Far below its 52-week high. info
No clear trend: the price is moving around its moving averages. It has dropped well below them. Volume is heavier on down days. info
From our AI technical analysis of the chart. info NA
Candle Patterns info NA
No recent price targets, so based on how targets have been revised. info
Recent news mostly negative. info
Holdings' Sentiment info NA
Institutions net +5.23% of shares in their latest 13F filings: 118 holders increased, 74 decreased (quarter to 30 Sep 2026). info
Short interest +0.6% from 31 Aug to 30 Oct 2026, 9.6 days to cover (FINRA). info
Insider Activity info NA
Market environment cautious. info
Sector lagging the market.
The pillars disagree, so the score is softened.
Below its medium-term trend line. info
Price is near its 52-week average. Up over 5 years. info
Short-term momentum falling. info
Price is near support. Levels trending down. info
Final Score -1.28
Show all

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock Omeros Corporation Mixed Bullish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B Score
OMER - - - - -1.3
HLVX 103 M - - 0.710 0.0
MEIP 49 M - - - 0.0
SONN 33 M - - 2.07 -1.4
INAB - - - 0.570 -2.5
ANIX - - - 6.26 -1.6

Select this tab to load the latest available analysis.

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Sector Healthcare
Industry Biotechnology
Investment Style Small Value
% Held by Insiders 4.40%
% Held by Institutions 47.30%

No data within this time range.

No data within this time range.

Institutions

Institutional ownership: 57.08%

Positions Holders Shares
Increased 118 7,503,141
Decreased 74 5,004,246
New 46 3,662,204
Sold out 24 2,294,472

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

Short Interest

Settlement Shares Days to cover
30 Oct 2026 12,833,757 9.6
15 Oct 2026 11,428,767 12.2
30 Sep 2026 11,382,531 6.9
15 Sep 2026 12,491,576 9.3
31 Aug 2026 12,758,406 7.3
14 Aug 2026 14,639,133 4.9

FINRA short interest via Nasdaq, reported twice a month.

2 Positive 3 Negative 7 Neutral
Date Type Details
18 Nov 2026 Yahoo Finance Omeros (OMER) Just Gave Investors Another Reason to Sell
Omeros Corp. (NASDAQ:OMER) is one of the 10 Stocks Investors Are Fleeing. Omeros Corp. fell 16.55 percent on Tuesday to close at $13.92 apiece, after incurring wider losses in the third quarter of the year. In an updated report, the company said that its net loss fell by 85 percent to $57.3 million…
17 Nov 2026 Yahoo Finance OMER Stock Eyes Worst Day In Nearly 18 Months With European Yartemlea Setback, Paper Losses Hitting Shares
CEO Demopulos said the company is now shifting its near-term regulatory strategy outside the European Union.
17 Nov 2026 Yahoo Finance Omeros (OMER) Q3 2026 Earnings Call Transcript
YARTEMLEA gained hospital access as gross product revenue rose 30% this quarter.
17 Nov 2026 Yahoo Finance Omeros Corporation Q3 2026 Earnings Call Summary
Moby summary of Omeros Corporation's Q3 2026 earnings call…
17 Nov 2026 Yahoo Finance Omeros Corp (OMER) Q3 2026 Earnings Call Highlights: YARTEMLEA Sales Surge 30% as Operating ...
Omeros Corp (OMER) posted $41.8 million in YARTEMLEA gross sales and $13.3 million in positive operating cash flow, though a $62 million non-cash charge drove a GAAP net loss.
16 Nov 2026 Yahoo Finance Omeros Q3 Earnings Call Highlights
Omeros (NASDAQ:OMER) reported higher third-quarter sales of its transplant complication treatment YARTEMLEA and a second consecutive quarter of positive operating cash flow, while a non-cash adjustment tied to its convertible notes pushed the company to a net loss. YARTEMLEA generated $35.9 million…
16 Nov 2026 Yahoo Finance Omeros falls 10% despite revenue beat
Investing.com -- Omeros Corporation (NASDAQ:OMER) reported third-quarter results that exceeded analyst expectations for both revenue and earnings, but shares tumbled 10% in after-hours trading Monday as the company posted a widened GAAP net loss.
16 Nov 2026 Yahoo Finance Omeros (OMER) Surpasses Q3 Earnings and Revenue Estimates
Omeros (OMER) delivered earnings and revenue surprises of +220.00% and +16.29%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
16 Nov 2026 Yahoo Finance Omeros: Q3 Earnings Snapshot
SEATTLE (AP) — SEATTLE (AP) — Omeros Corporation (OMER) on Monday reported a loss of $57.On a per-share basis, the Seattle-based company said it had a loss of 79 cents.
16 Nov 2026 Yahoo Finance Omeros Corporation Reports Third Quarter 2026 Financial Results
SEATTLE, November 16, 2026--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2026, which include:…
12 Nov 2026 Yahoo Finance Omeros (OMER) Stock May Be Undervalued After Investor Fraud Probe
Omeros has been on a dramatic multi year run, yet recent headlines and price swings leave a straightforward question for investors who focus on fundamentals. Is the current share price properly supported by what the business is earning today and what those earnings suggest about the future? Over…
10 Nov 2026 Yahoo Finance Omeros Corporation to Announce Third Quarter Financial Results on November 16, 2026
SEATTLE, November 10, 2026--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the third quarter of 2026 on Monday, November 16, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time…
16 Oct 2026 Yahoo Finance Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index down 0.1% and the…
16 Oct 2026 Yahoo Finance Omeros Shares Slide After CHMP Upholds Negative Opinion On Drug; Analyst Sees Buying Opportunity At $16
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a negative opinion on Omeros’ marketing authorization application for narsoplimab, sold as Yartemlea in the United States, the company said on Friday.
16 Oct 2026 Yahoo Finance Sector Update: Healthcare Stocks Mixed Friday Afternoon
Healthcare stocks were mixed Friday afternoon, with the NYSE Healthcare Index up 0.1% and the State…
16 Oct 2026 Yahoo Finance Omeros Shares Fall 4% as European Regulators Uphold Negative Opinion on Narsoplimab
Omeros Corporation (NASDAQ:OMER) shares declined 4% in Friday morning trading after the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) maintained its negative opinion on the company’s marketing authorisation application for narsoplimab. The decision followed…
16 Oct 2026 Yahoo Finance Omeros shares slide following European regulatory setback for Narsoplimab
Investing.com -- Shares of Omeros Corporation (NASDAQ: OMER) retreated 4% in Friday morning trading after the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) maintained a negative opinion on the marketing authorization application for its drug, narsoplimab.
16 Oct 2026 Yahoo Finance Omeros Faces Second Rejection Of Narsoplimab In Europe – OMER Stock Falls Below Key Support For First Time In Nearly 3 Months
European regulators rejected Omeros’ application for Narsoplimab, which is used to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy.
16 Oct 2026 Yahoo Finance Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA
SEATTLE, October 16, 2026--Omeros Corporation (Nasdaq: OMER) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the company’s marketing authorization application (MAA) for narsoplimab for the treatment…
23 Sep 2026 Yahoo Finance Dow Jones Futures Fall After Nasdaq Hits New High; Sandisk, Micron Trigger Buy Signals
The Nasdaq hit a new high with memory giants Sandisk and Micron flashing buy signals. But financials are struggling.
22 Sep 2026 Yahoo Finance NTRA Stock Hits All-Time High, OMER Stock Scales 5-Year Peak – What’s Driving Investors’ Enthusiasm Today?
Natera’s Signatera test secured a key regulatory approval, while Cantor raised its sales expectations for Omeros’ lead drug, Yartemlea.
28 Aug 2026 Yahoo Finance What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?
Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.
25 Aug 2026 Yahoo Finance Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy?
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
19 Aug 2026 Yahoo Finance Omeros (OMER) Q2 2026 Earnings Call Transcript
Yartemlia generated $32.2M in gross sales during its first full quarter on market.
Show more

Recent Signals candle patterns and EMA crosses

▼ Bearish EMA cross Last session · 18 Nov
Medium term · EMA 20/50
The 20-day EMA crossed below the 50-day: the medium-term trend turned down.

Technical Setup Medium

Trend order
Slope
Entry
Volume
No clear trend: the price is moving around its moving averages. It has dropped well below them. Volume is heavier on down days.
Nearest support: 13.68 – 14.38 · moderate level
Nearest resistance: 14.68 – 15.58 · strong level

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria